HUP1100444A2 - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
HUP1100444A2
HUP1100444A2 HU1100444A HUP1100444A HUP1100444A2 HU P1100444 A2 HUP1100444 A2 HU P1100444A2 HU 1100444 A HU1100444 A HU 1100444A HU P1100444 A HUP1100444 A HU P1100444A HU P1100444 A2 HUP1100444 A2 HU P1100444A2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
HU1100444A
Other languages
Hungarian (hu)
Inventor
Ahmed Dr Sabry
Attila Dr Kolonics
Janos Egri
Laszlo Dr Vigh
Gordon Department Of Phisiology Dr Linch
Stefan Department Of Physiology Dr Gehrig
Lars Dr Larson
Kalman Dr Tory
Nagy Peter Dr Literati
Mark Dr Febbraio
Original Assignee
Pharma Gene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Gene Sa filed Critical Pharma Gene Sa
Priority to HU1100444A priority Critical patent/HUP1100444A2/en
Priority to PCT/HU2012/000070 priority patent/WO2013024311A1/en
Publication of HUP1100444A2 publication Critical patent/HUP1100444A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
HU1100444A 2011-08-17 2011-08-17 Pharmaceutical composition HUP1100444A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
HU1100444A HUP1100444A2 (en) 2011-08-17 2011-08-17 Pharmaceutical composition
PCT/HU2012/000070 WO2013024311A1 (en) 2011-08-17 2012-08-14 Amidoxime derivatives for the prevention and/or treatment of muscle atrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1100444A HUP1100444A2 (en) 2011-08-17 2011-08-17 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
HUP1100444A2 true HUP1100444A2 (en) 2013-02-28

Family

ID=89990395

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1100444A HUP1100444A2 (en) 2011-08-17 2011-08-17 Pharmaceutical composition

Country Status (2)

Country Link
HU (1) HUP1100444A2 (en)
WO (1) WO2013024311A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263105A1 (en) 2016-07-01 2018-01-03 Montana State University Use of bgp15 to treat familial dysautonomia
PT3634411T (en) 2017-06-08 2023-11-28 N Gene Res Laboratories Inc Methods for treating nash and for preventing nash-induced hcc
HUP1800298A1 (en) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Combination of beta blocker and hydroximic acid derivative with reduced side effects

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187220A (en) 1977-08-30 1980-02-05 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
US6884424B2 (en) 1995-12-22 2005-04-26 N-Gene Research Laboratories Inc. Method for treating the pathological lesions of the skin that develop by ultraviolet radiation of the sunlight
US6458371B1 (en) 1995-12-22 2002-10-01 Medgene, Limited Cosmetic composition and a method for the prevention and/or reduction of the photoaging processes of the skin
HUP9701080A3 (en) 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
AU5296799A (en) 1998-08-03 2000-02-28 N-Gene Kutato Kft. Pharmaceutical compositions against autoimmune diseases
PL358393A1 (en) 2000-03-20 2004-08-09 N-Gene Research Laboratories Inc. Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
CN1270713C (en) 2001-07-17 2006-08-23 N基因研究实验室公司 Synergistic pharmaceutical combination for prevention or treatment of diabetes
HUP0401177A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0401176A2 (en) 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition having prpkinetic effect
HUP0500145A2 (en) 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
US7763601B2 (en) 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080108602A1 (en) 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US20090281143A1 (en) 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity

Also Published As

Publication number Publication date
WO2013024311A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
AP3864A (en) Pharmaceutical composition
GB201113662D0 (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
HK1199824A1 (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
GB201118232D0 (en) Pharmaceutical composition
EP2832730A4 (en) Mirabegron-containing pharmaceutical composition
EP2702989A4 (en) Stable pharmaceutical composition
HK1189158A1 (en) Pharmaceutical composition
EP2769718A4 (en) Medicinal composition
EP2731610A4 (en) Pharmaceutical combination
GB201106520D0 (en) Pharmaceutical compounds
GB201118181D0 (en) Pharmaceutical compositions
EP2727593A4 (en) Nicorandil-containing pharmaceutical composition
EP2711010A4 (en) Pharmaceutical composition
HUP1100444A2 (en) Pharmaceutical composition
ZA201502987B (en) Pharmaceutical composition
ZA201308414B (en) Solid pharmaceutical composition
EP2897590A4 (en) Pharmaceutical composition
HUP1100445A2 (en) Pharmaceutical composition
EP2714715A4 (en) Pharmaceutical compositions
EP2851078A4 (en) Pharmaceutical composition
ZA201309537B (en) Pharmaceutical composition comprising fexofedine
EP2727594A4 (en) Novel pharmaceutical composition
ZA201400751B (en) Pharmaceutical composition

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees
GB9A Succession in title

Owner name: PHARMA-GENE SA, CH

Free format text: FORMER OWNER(S): DR. HAZAY BALAZS, HU